CHARGED ALPHATMFrontier AI stock research

RVTY · NYSE

Revvity, Inc.

Diagnostics & Research · United States

USD 149.09-1.3% daily changeQuote 2026-09-28 · USD
Market cap (USD)
US$16.64B
Trailing P/E
71.34x
Forward P/E
25.31x
Quarterly revenue growth
1.3%
Trailing net margin
8.2%
Indicated dividend yield
0.2%

Snapshot 2026-09-28 · Latest financial period 2026-07-05 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-10-26 (provider estimate, not issuer-confirmed).

Company background

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Company website

Q2 2026

Go beyond the headline.

Revvity (RVTY) Q2 2026 Earnings: A 20-Cent Beat, 11 Cents A Tariff Refund

Published 2026-08-10

Comparable businesses

RVTY peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricRVTYRevvity, Inc.Snapshot 2026-09-28Financial period: 2026-07-05MEDPMedpace Holdings, Inc.Snapshot 2026-09-28Financial period: 2026-06-30CRLCharles River Laboratories International, Inc.Snapshot 2026-09-28Financial period: 2026-06-27Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$16.64BUS$17.18BUS$14.07BUS$15.63Bn=2
Forward P/EProvider forward earnings estimate25.31x31.88x23.01x27.44xn=2
EV / EBITDAEnterprise value / trailing EBITDA21.90x27.68x19.87x23.77xn=2
Revenue growthLatest quarter vs prior-year quarter1.3%17.2%-2.7%7.2%n=2
Operating marginLatest reported quarter17.1%20.8%15.1%17.9%n=2
Free cash flow yieldTrailing cash flow / market cap3.6%3.0%3.3%3.2%n=2
Net debt / EBITDANet debt / trailing EBITDA2.65x-0.59x3.35x1.38xn=2
Debt / equityTotal debt / positive book equity0.46x0.33x1.05x0.69xn=2
Trailing P/ETrailing twelve-month earnings71.34x36.17x——
Price / bookPrice / positive book equity per share2.30x39.60x4.91x22.26xn=2
EV / salesEnterprise value / trailing revenue6.59x6.08x4.22x5.15xn=2
Earnings growthLatest quarter vs prior-year quarter1.2%37.1%——
Gross marginTrailing twelve months55.0%72.4%34.6%53.5%n=2
Net marginTrailing twelve months8.2%17.7%-6.0%5.9%n=2
Return on equityProvider trailing return; positive equity only3.2%162.2%-7.5%77.3%n=2
Free cash flow marginTrailing free cash flow / revenue20.8%18.3%11.7%15.0%n=2
Dividend yieldIndicated annual dividend / price0.2%———
Earnings payoutProvider trailing dividend payout13.5%0.0%0.0%0.0%n=2
Current ratioCurrent assets / current liabilities1.80x0.73x1.35x1.04xn=2
BetaProvider historical market sensitivity1.091.151.411.28n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-09-28. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for RVTY

All available reporting periods
Q2 20262026-08-10

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.